MDC Max Delbrück Center for Molecular Medicine in the Helmholtz Association
The MDC Max Delbrück Center for Molecular Medicine in the Helmholtz Association ranks among the top institutions in the world for basic biomedical research. MDC scientists use state-of-the-art methods of molecular biology and genetic engineering in order to understand the development of complex diseases at their origin, in the genes. On this basis, they seek to develop new methods to diagnose, treat and prevent diseases. Research activities at the MDC are divided into four main areas: cardiovascular and metabolic diseases, cancer, diseases of the nervous system and medical systems biology. MDC researchers collaborate closely with the Charité in the Experimental and Clinical Research Center and also with biotech companies located on Campus Berlin-Buch. The MDC currently employs approximately 1,700 staff members, including guest scientists, and has state-of-the-art technology platforms such as 7 Tesla ultra high field MRI, electron microscopy or bioinformatics.
Leibniz Research Institute for Molecular Pharmacology (FMP)
How do diseases develop? Which drugs can specifically target and intervene in the biochemistry of the body? Research activities at the Leibniz Research Institute for Molecular Pharmacology (FMP), Germany’s only non-university research institute for pharmacology, are concerned with these questions. Chemists, biologists, pharmacologists, physicists and physicians collaborate closely to lay the basis for the development of future drugs.
The FMP cooperates with other Berlin research institutions such as the Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin and is part of several research projects, such as the Neurocure cluster of excellence. The institute is also one of the initiators of the large-scale European project EU-OPENSCREEN, in which institutions from various European countries want to coordinate the search for new drugs, and part of the new European network “Instruct”, which seeks to link the highly sophisticated technologies in structural biology.
The institute has a staff of 300 employees and is a member of the Leibniz Association and the Forschungsverbund Berlin e.V. (Berlin Research Association).
Towards a cell-based interceptive medicine in Europe
Hundreds of researchers, clinicians, industry leaders and policy makers from all around Europe are united by a vision of how to revolutionize healthcare. In a perspective in Nature and the LifeTime St...more ...
ERC funding for pioneering research
Two MDC scientists – Kathrin de Rosa and Ilaria Piazza – have earned ERC Starting Grants to fuel their pioneering research. They are seeking answers to questions that may one day change the way we app...more ...
In pursuit of the origin and role of ecDNA
How does cancer develop and how does it progress? Dr. Anton Henssen from the Experimental and Clinical Research Center (ECRC) wants to find out more about circular DNA in order to use its cancer cell-...more ...
DIGITALE LIFE SCIENCES – Workshops zu den Grundlagen der Bioinformatik und zum Labor 4.0
Neuer Kurs für Technische Angestellten und Laboranten in den Life Sciences: Überblick über aktuelle Themen zur Bioinformatik, Digitalisierung und Automatisierungmore ...
WEITERBILDUNGSTAG LABOR 4.0 FÜR TECHNISCHE ANGESTELLTE UND LABORANT*INNEN
Fachkraft für Molekularbiologie (TÜV)
Das 11-tägige Seminar vermittelt Grundlagen der wichtigsten Labormethoden der modernen Molekularbiologie und Einblicke in die klinische Forschungmore ...